Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Cancer Group, China
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Allogene Therapeutics
Genmab
Genmab
Genmab
Case Comprehensive Cancer Center
Children's Oncology Group
St. Jude Children's Research Hospital
Novartis
Merck Sharp & Dohme LLC
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Celgene
M.D. Anderson Cancer Center
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
Regeneron Pharmaceuticals
Center for International Blood and Marrow Transplant Research
Regeneron Pharmaceuticals
Mayo Clinic
University of Wisconsin, Madison
Massachusetts General Hospital
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Celgene
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Children's Oncology Group
M.D. Anderson Cancer Center
University of Rochester
Gilead Sciences